A detailed history of Lindbrook Capital, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 2,500 shares of RLMD stock, worth $950. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,500
Previous 2,500 -0.0%
Holding current value
$950
Previous $7,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 24, 2023

SELL
$2.17 - $35.84 $208 - $3,440
-96 Reduced 3.7%
2,500 $0
Q3 2022

Nov 10, 2022

BUY
$18.3 - $37.02 $1,335 - $2,702
73 Added 2.89%
2,596 $96,000
Q2 2022

Aug 01, 2022

BUY
$16.5 - $30.34 $379 - $697
23 Added 0.92%
2,523 $48,000
Q4 2021

Jan 18, 2022

BUY
$16.93 - $26.82 $42,325 - $67,050
2,500 New
2,500 $56,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.